VFValérie Favède

Valérie Favède

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Valérie Favède has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Greninger

    Department of Laboratory Medicine and Pathology, University of Washington Medical Center

    1 shared publication
  • Ana Zarubica

    Centre d’Immunophénomique, Aix Marseille Université, Inserm, CNRS, PHENOMIN, Celphedia, Marseille, France

    1 shared publication
  • Anne Moscona

    Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons

    1 shared publication
  • Anne-Geneviève Marcelin

    Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, AP-HP, Hôpitaux Universitaires Pitié-Salpêtrière-Charles Foix, Laboratoire de Virologie, 75013 Paris, France

    1 shared publication
  • Bernard Malissen

    Centre d’Immunophénomique, Aix Marseille Université, Inserm, CNRS, PHENOMIN, Celphedia, Marseille, France

    1 shared publication
  • Branka Horvat

    CIRI, Centre International de Recherche en Infectiologie, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Lyon, France

    1 shared publication

Latest Publications

  • Open Access

    Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity

    by Said Mougari, Valérie Favède, Camilla Predella, Olivier Reynard, Stephanie Durand, Magalie Mazelier, Edoardo Pizzioli, Didier Decimo, Francesca T. Bovier, Lauren M. Lapsley, et al.

    We have assessed antiviral activity and induction of protective immunity of fusion-inhibitory lipopeptides derived from the C-terminal heptad-repeat domain of SARS-CoV-2 spike glycoprotein in transgenic mice expressing human ACE2 (K18-hACE2). The lipopeptides block SARS-CoV-2 infection in cell lines and lung-derived organotypic cultures. Intranasal administration in mice allows the maintenance of homeostatic transcriptomic immune profile in lungs, prevents body-weight loss, decreases viral load and shedding, and protects mice from death caused by SARS-CoV-2 variants. Prolonged administration of high-dose lipopeptides has neither adverse effects nor impairs peptide efficacy in subsequent SARS-CoV-2 challenges. The peptide-protected mice develop cross-reactive neutralizing antibodies against both SARS-CoV-2 used for the initial infection and recently circulating variants, and are completely protected from a second lethal infection, suggesting that they developed SARS-CoV-2-specific immunity. This strategy provides an additional antiviral approach in the global effort against COVID-19 and may contribute to development of rapid responses against emerging pathogenic viruses.